CN118303531A - Additive composition and application thereof - Google Patents
Additive composition and application thereof Download PDFInfo
- Publication number
- CN118303531A CN118303531A CN202410586060.XA CN202410586060A CN118303531A CN 118303531 A CN118303531 A CN 118303531A CN 202410586060 A CN202410586060 A CN 202410586060A CN 118303531 A CN118303531 A CN 118303531A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- additive composition
- auxiliary agent
- mass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K61/00—Culture of aquatic animals
- A01K61/10—Culture of aquatic animals of fish
- A01K61/13—Prevention or treatment of fish diseases
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Environmental Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Dermatology (AREA)
- Insects & Arthropods (AREA)
- Birds (AREA)
- Pain & Pain Management (AREA)
Abstract
Description
技术领域Technical Field
本发明涉及一种添加剂组合物及其应用,属于生物技术领域。The invention relates to an additive composition and application thereof, belonging to the field of biotechnology.
背景技术Background technique
中华鲟是我国特有的大型江海洄游性鱼类,被列为国家一级重点保护水生动物。由于受多种因素的影响,其自然种群资源急剧下降,人工保种已成为该物种保护的重要途径。随着中华鲟迁地保护规模的扩大以及集约化程度的不断提高,病害问题也日趋增多。近年来,在中华鲟养殖过程中出现一种以体表存在红色小脓包,小脓包四周伴有红血丝为主要症状的新型皮肤类疾病,对中华鲟健康养殖具有一定的影响。目前,常规的药物及使用方法对该病的防治效果不佳。The Chinese sturgeon is a large river and sea migratory fish unique to my country and is listed as a national first-class protected aquatic animal. Due to the influence of various factors, its natural population resources have declined sharply, and artificial seed conservation has become an important way to protect this species. With the expansion of the scale of ex situ protection of the Chinese sturgeon and the continuous improvement of the degree of intensiveness, disease problems are also increasing. In recent years, a new type of skin disease has appeared in the breeding process of Chinese sturgeon, with the main symptoms of small red pustules on the body surface and red blood around the pustules, which has a certain impact on the healthy breeding of Chinese sturgeon. At present, conventional drugs and usage methods are not effective in preventing and treating this disease.
因此,如何提高中华鲟免疫力以及中华鲟皮肤病治愈率,促进中华鲟规模化养殖成为本领域目前亟待解决的问题。Therefore, how to improve the immunity of Chinese sturgeon and the cure rate of Chinese sturgeon skin diseases and promote large-scale breeding of Chinese sturgeon has become an urgent problem to be solved in this field.
发明内容Summary of the invention
本发明提供一种添加剂组合物,该添加剂组合物用于中华鲟养殖后,能够显著提高中华鲟免疫力,提高中华鲟皮肤病治愈率。The invention provides an additive composition. After being used in Chinese sturgeon breeding, the additive composition can significantly improve the immunity of Chinese sturgeon and improve the cure rate of Chinese sturgeon skin diseases.
本发明还提供一种饲料,该饲料包括上述添加剂组合物,因此能够明显提高中华鲟皮肤病治愈率,促进中华鲟规模化养殖。The present invention also provides a feed, which comprises the additive composition, thereby being able to significantly improve the cure rate of skin diseases of Chinese sturgeon and promote large-scale breeding of Chinese sturgeon.
本发明还提供一种中华鲟的饲养方法,饲养过程中使用了上述饲料,因此能够显著提高中华鲟皮肤病治愈率,助力中华鲟规模化养殖。The present invention also provides a method for breeding Chinese sturgeon. The above-mentioned feed is used in the breeding process, so the cure rate of skin diseases of Chinese sturgeon can be significantly improved, and the large-scale breeding of Chinese sturgeon can be promoted.
本发明还提供一种上述添加剂组合物作为制备治疗中华鲟皮肤病的药物中的应用,在制备治疗中华鲟皮肤病的药物过程中,使用了上述添加剂组合物,对治疗中华鲟皮肤病具有显著的效果。The present invention also provides an application of the additive composition as a medicine for preparing a medicine for treating a skin disease of a Chinese sturgeon. The additive composition is used in the process of preparing a medicine for treating a skin disease of a Chinese sturgeon, and has a significant effect on treating the skin disease of a Chinese sturgeon.
本发明还提供一种药物组合物,该药物组合物包括上述添加剂组合物,因此该药物组合物能够有效治疗中华鲟皮肤病,促进中华鲟规模化养殖。The present invention also provides a pharmaceutical composition, which includes the above-mentioned additive composition, so the pharmaceutical composition can effectively treat the skin disease of Chinese sturgeon and promote the large-scale breeding of Chinese sturgeon.
本发明一方面提供一种添加剂组合物,所述添加剂组合物按照质量份包括0.6-0.9份维生素A、10-20份泛酸钙、2-5份叶酸、100-800份维生素C、13.36-26.72份维生素E、15-30份维生素K3、8000-12000份板蓝根多糖。In one aspect, the present invention provides an additive composition, which comprises, by weight, 0.6-0.9 parts of vitamin A, 10-20 parts of calcium pantothenate, 2-5 parts of folic acid, 100-800 parts of vitamin C, 13.36-26.72 parts of vitamin E, 15-30 parts of vitamin K 3 , and 8000-12000 parts of Radix Isatidis polysaccharide.
如上所述的添加剂组合物,所述添加剂组合物按照质量份0.8份维生素A、16份泛酸钙、4份叶酸、600份维生素C、20.04份维生素E、24份维生素K3、10000份板蓝根多糖。The additive composition as described above comprises, by weight, 0.8 parts of vitamin A, 16 parts of calcium pantothenate, 4 parts of folic acid, 600 parts of vitamin C, 20.04 parts of vitamin E, 24 parts of vitamin K 3 , and 10,000 parts of Radix Isatidis polysaccharide.
本发明再一方面提供一种饲料,包括如上所述的添加剂组合物。In another aspect, the present invention provides a feed comprising the additive composition as described above.
如上所述的饲料,还包括常规饲料,所述添加剂组合物与所述常规饲料的质量比为1.1:100。The feed as described above also includes conventional feed, and the mass ratio of the additive composition to the conventional feed is 1.1:100.
本发明再一方面提供一种中华鲟的饲养方法,采用如上所述的饲料对中华鲟进行饲养。In another aspect, the present invention provides a method for raising Chinese sturgeon, which comprises raising Chinese sturgeon using the feed as described above.
如上所述的饲养方法,饲养过程中日投喂量为1.0%-1.3%,日投喂频次为2次/天,投喂时间间隔为12小时。In the feeding method as described above, the daily feeding amount during the feeding process is 1.0%-1.3%, the daily feeding frequency is 2 times/day, and the feeding interval is 12 hours.
本发明再一方面提供一种如上所述的添加剂组合物作为制备治疗中华鲟皮肤病的药物中的应用。In another aspect, the present invention provides a use of the additive composition as described above in preparing a medicament for treating skin diseases of Chinese sturgeon.
本发明再一方面提供一种药物组合物,包括如上所述的添加剂组合物。In another aspect, the present invention provides a pharmaceutical composition comprising the additive composition as described above.
如上所述的药物组合物,还包括第一辅助药剂,所述第一辅助药剂按照质量份包括5-20份氟甲砜霉素、0.2份三磷酸腺苷二钠、0.5份辅酶A,100份复方氨基酸。The pharmaceutical composition as described above further comprises a first auxiliary agent, which comprises, by weight, 5-20 parts of fluoroquinolone, 0.2 parts of adenosine triphosphate disodium, 0.5 parts of coenzyme A, and 100 parts of compound amino acids.
如上所述的药物组合物,还包括第二辅助药剂,所述第二辅助药剂按照质量份包括1份紫草油、2份红霉素软膏、1份云南白药。The pharmaceutical composition as described above further comprises a second auxiliary agent, which comprises, by weight, 1 part of lithospermum oil, 2 parts of erythromycin ointment, and 1 part of Yunnan Baiyao.
本发明提供的添加剂组合物由特定组分的原料组成,在特定组分的原料的协同作用下,有助于促进中华鲟对蛋白质的吸收利用,促进表皮细胞的发育与再生,促进血液凝固,提高中华鲟机体免疫能力,有效控制感染,增强中华鲟机体抗应激、抗炎症、抗氧化能力,有效防控中华鲟皮肤病,对中华鲟物种保护起到重要的保障作用。The additive composition provided by the present invention is composed of raw materials of specific components. Under the synergistic effect of the raw materials of the specific components, it helps to promote the absorption and utilization of protein by the Chinese sturgeon, promote the development and regeneration of epidermal cells, promote blood coagulation, improve the immune ability of the Chinese sturgeon, effectively control infection, enhance the anti-stress, anti-inflammatory and antioxidant capabilities of the Chinese sturgeon, effectively prevent and control Chinese sturgeon skin diseases, and play an important role in protecting the Chinese sturgeon species.
本发明提供的饲料包括上述添加剂,因此能够显著提高中华鲟免疫力,提高中华鲟皮肤病的治愈率。The feed provided by the present invention includes the above-mentioned additives, and thus can significantly improve the immunity of Chinese sturgeons and increase the cure rate of Chinese sturgeon skin diseases.
本发明提供的饲养方法使用了上述饲料,有助于增强中华鲟免疫力,增强中华鲟抗皮肤病的能力。The feeding method provided by the present invention uses the above feed, which is helpful to enhance the immunity of Chinese sturgeon and enhance the ability of Chinese sturgeon to resist skin diseases.
本发明提供上述添加剂组合物作为制备治疗中华鲟皮肤病的药物中的应用,在制备治疗中华鲟皮肤病的药物过程中,使用了上述添加剂组合物,对治疗中华鲟皮肤病具有显著的效果。The present invention provides the use of the additive composition as a drug for preparing a drug for treating a Chinese sturgeon skin disease. In the process of preparing a drug for treating a Chinese sturgeon skin disease, the additive composition is used, which has a significant effect on treating the Chinese sturgeon skin disease.
本发明提供的药物组合物包括上述添加剂组合物,因此该药物组合物能够有效治疗中华鲟皮肤病,促进中华鲟规模化养殖。The pharmaceutical composition provided by the present invention comprises the above-mentioned additive composition, so the pharmaceutical composition can effectively treat the skin disease of Chinese sturgeon and promote the large-scale breeding of Chinese sturgeon.
附图说明BRIEF DESCRIPTION OF THE DRAWINGS
图1为本发明中的感染皮肤病的中华鲟局部照片;FIG1 is a partial photo of a Chinese sturgeon infected with skin disease in the present invention;
图2为本发明一具体实施方式中病原微生物分离照片;FIG2 is a photograph of pathogenic microorganism separation in one specific embodiment of the present invention;
图3为本发明一具体实施方式中病原微生物革兰氏染色图;FIG3 is a Gram staining diagram of pathogenic microorganisms in a specific embodiment of the present invention;
图4为本发明一具体实施方式中电泳检测PCR产物图。FIG. 4 is a diagram showing electrophoresis detection of PCR products in a specific embodiment of the present invention.
具体实施方式Detailed ways
为使本发明的目的、技术方案和优点更加清楚,下面将结合本发明的实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution in the embodiment of the present invention will be clearly and completely described below in combination with the embodiment of the present invention. Obviously, the described embodiment is a part of the embodiment of the present invention, not all the embodiments. Based on the embodiment of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
本发明一方面提供一种添加剂组合物,按照质量份包括0.6-0.9份维生素A、10-20份泛酸钙、2-5份叶酸、100-800份维生素C、13.36-26.72份维生素E、15-30份维生素K3、8000-12000份板蓝根多糖。In one aspect, the present invention provides an additive composition, which comprises, by weight, 0.6-0.9 parts of vitamin A, 10-20 parts of calcium pantothenate, 2-5 parts of folic acid, 100-800 parts of vitamin C, 13.36-26.72 parts of vitamin E, 15-30 parts of vitamin K 3 , and 8000-12000 parts of Radix Isatidis polysaccharide.
本发明提供的添加剂组合物由特定组分的原料组成,能够用于防治中华鲟皮肤病。The additive composition provided by the invention consists of raw materials of specific components and can be used for preventing and treating skin diseases of Chinese sturgeon.
本发明不限定中华鲟皮肤病的病原微生物的确定方式,可以采用本领域常见的诊断方法对患病中华鲟进行诊断。The present invention does not limit the method for determining the pathogenic microorganisms of the skin disease of Chinese sturgeon, and the diseased Chinese sturgeon can be diagnosed by the common diagnostic methods in the art.
例如,当中华鲟胸鳍、背鳍、臀鳍等基部或其它表皮部位出现红色小脓包,小脓包四周伴有红血丝症状,如图1所示时,采用无菌注射器从病鱼红色小脓包中抽取1mL血水,在无菌条件下接种至BHIA平板,培养24-48小时,从初培养的平皿中挑取典型优势菌落,转接至BHIA平板进行纯化培养。纯化培养24小时后观察菌落形态特征,如图2所示,表现为圆形、表面光滑、不透明、奶白色,如图3所示,革兰氏染色结果显示为革兰氏阳性菌,随后将纯化后的菌株接种至BHI液体培养基中,28℃培养16-24小时,采用16srDNA检测技术,得到电泳检测PCR产物图,如图4所示,确定病原微生物。For example, when red pustules appear at the base of the pectoral fin, dorsal fin, anal fin or other epidermal parts of the Chinese sturgeon, and the pustules are surrounded by red blood streaks, as shown in Figure 1, a sterile syringe is used to extract 1 mL of blood from the red pustules of the diseased fish, and inoculated to the BHIA plate under sterile conditions, cultured for 24-48 hours, and typical dominant colonies are picked from the initial culture plate and transferred to the BHIA plate for purification culture. After 24 hours of purification culture, the morphological characteristics of the colonies are observed, as shown in Figure 2, showing a round, smooth surface, opaque, milky white color, as shown in Figure 3, and the Gram staining results show Gram-positive bacteria. Subsequently, the purified strains are inoculated into BHI liquid culture medium, cultured at 28°C for 16-24 hours, and the 16srDNA detection technology is used to obtain the electrophoresis detection PCR product map, as shown in Figure 4, to determine the pathogenic microorganism.
本发明中的维生素A能够保护上皮组织的健全与完整、促进粘膜和皮肤的发育与再生;促进结缔组织中多糖的合成、维护细胞膜和细胞器膜结构的完整功能;维护骨骼的正常生长和修补;维持神经细胞的正常功能;提高机体的免疫能力。The vitamin A in the present invention can protect the health and integrity of epithelial tissue, promote the development and regeneration of mucous membranes and skin; promote the synthesis of polysaccharides in connective tissue, maintain the integrity of cell membranes and organelle membrane structures; maintain the normal growth and repair of bones; maintain the normal function of nerve cells; and improve the body's immune ability.
泛酸钙即维生素B3,能够参与脂肪酸合成、降解,柠檬酸循环,胆碱乙酰化及抗体的合成,促进营养素的利用。Calcium pantothenate, also known as vitamin B 3 , can participate in fatty acid synthesis and degradation, citric acid cycle, choline acetylation and antibody synthesis, and promote the utilization of nutrients.
叶酸即维生素B11,在体内经维生素C作用转变成四氢叶酸,四氢叶酸为羰基团转移酶的辅酶,影响核酸的合成,促进蛋白质和新细胞的形成。Folic acid is vitamin B11 , which is converted into tetrahydrofolic acid by vitamin C in the body. Tetrahydrofolic acid is a coenzyme of carbonyl transferase, which affects the synthesis of nucleic acids and promotes the formation of proteins and new cells.
维生素C参与机体氧化还原过程影响核酸的形成、铁的吸收、造血机能、解毒及免疫功能,主要影响水生动物的非特异性免疫,促进抗体的形成,从而提高免疫力。Vitamin C participates in the body's redox process, affecting the formation of nucleic acids, iron absorption, hematopoiesis, detoxification and immune function. It mainly affects the nonspecific immunity of aquatic animals, promotes the formation of antibodies, and thus improves immunity.
维生素E是体内的生理性抗氧化剂,能降低组织对氧的消耗,增强线粒体功能,影响核酸代谢和多种酶的功能;具有非特异性解毒作用,延长细胞生存期,降解脂质,有助于创伤恢复。Vitamin E is a physiological antioxidant in the body that can reduce tissue oxygen consumption, enhance mitochondrial function, affect nucleic acid metabolism and the functions of various enzymes; it has a nonspecific detoxification effect, prolongs cell survival, degrades lipids, and helps trauma recovery.
维生素K3为抗凝血因子,促进凝血酶原的形成,维持正常的凝血时间;同时还具有强化肝脏解毒功能的作用。Vitamin K3 is an anticoagulant factor that promotes the formation of prothrombin and maintains normal coagulation time; it also has the effect of strengthening the liver's detoxification function.
板蓝根多糖是板蓝根中主要化学成分和生物活性的主要作用因子,具有抑菌、抗氧化、抗病毒、抗炎症、提高免疫能力等作用。Radix Isatidis polysaccharide is the main chemical component in Radix Isatidis and the main factor of biological activity. It has antibacterial, antioxidant, antiviral, anti-inflammatory, and immune-enhancing effects.
当上述组分按照上述质量份混合时,用于中华鲟皮肤病具有良好的效果,发明人分析认为,原因可能在于:特定质量份的各类组分组合后能够充分发挥各个组分之间的协同作用,促进中华鲟对蛋白质的吸收利用,促进表皮细胞的发育与再生,促进血液凝固,提高中华鲟机体免疫能力,有效控制感染,增强中华鲟机体抗应激、抗炎症、抗氧化能力,提高中华鲟皮肤病的治愈率。When the above components are mixed according to the above mass parts, they have a good effect on the skin disease of Chinese sturgeon. The inventors analyzed that the reason may be that the combination of various components in specific mass parts can give full play to the synergistic effect between the components, promote the absorption and utilization of protein by Chinese sturgeon, promote the development and regeneration of epidermal cells, promote blood coagulation, improve the immune ability of Chinese sturgeon, effectively control infection, enhance the anti-stress, anti-inflammatory and antioxidant capabilities of Chinese sturgeon, and improve the cure rate of skin disease of Chinese sturgeon.
进一步地,在本发明的一具体实施方式中,添加剂组合物按照质量份包括0.8份维生素A、16份泛酸钙、4份叶酸、600份维生素C、20.04份维生素E、24份维生素K3、10000份板蓝根多糖。Furthermore, in a specific embodiment of the present invention, the additive composition includes, by mass, 0.8 parts of vitamin A, 16 parts of calcium pantothenate, 4 parts of folic acid, 600 parts of vitamin C, 20.04 parts of vitamin E, 24 parts of vitamin K 3 , and 10,000 parts of Radix Isatidis polysaccharide.
当添加剂组合物的各类组分符合上述质量份时,制备得到的添加剂用于喂养感染皮肤病的中华鲟时,具有更高的治愈率,原因可能在于:(1)添加剂组合协同作用方面:多种维生素配比合理,协同增效,一是增强中华鲟机体的抗应激能力;二是促进血液凝固以及表皮细胞的发育与再生,对细菌性疾病的康复具有良好的功效;三是抑制致病菌的定居,控制疾病的发展;四是增强食欲,促进中华鲟对蛋白质的吸收利用。板蓝根多糖与多种维生素相结合,能够有效地提高中华鲟机体的免疫力,增强抗应激、抗炎症和抗氧化能力,从而达到良好的防治效果。(2)添加剂组合使用剂量方面:添加剂组合剂量在合适的安全剂量范围内,有效地起到了提高中华鲟机体免疫力,减少病原微生物侵害,促进疾病康复的作用。在使用过程中,不会出现因剂量不足造成疾病防治效果不佳,也不会出现因剂量过大造成对中华鲟机体损伤的不良影响。When the various components of the additive composition meet the above mass parts, the prepared additive has a higher cure rate when used to feed Chinese sturgeons infected with skin diseases. The reasons may be: (1) The synergistic effect of the additive combination: the ratio of multiple vitamins is reasonable, and the synergistic effect is enhanced. First, the anti-stress ability of the Chinese sturgeon is enhanced; second, blood coagulation and the development and regeneration of epidermal cells are promoted, which has a good effect on the recovery of bacterial diseases; third, the settlement of pathogenic bacteria is inhibited, and the development of the disease is controlled; fourth, appetite is enhanced, and the absorption and utilization of protein by the Chinese sturgeon is promoted. The combination of Radix Isatidis polysaccharides and multiple vitamins can effectively improve the immunity of the Chinese sturgeon, enhance the anti-stress, anti-inflammatory and antioxidant abilities, and thus achieve a good prevention and treatment effect. (2) The dosage of the additive combination: the dosage of the additive combination is within the appropriate safe dosage range, which effectively plays a role in improving the immunity of the Chinese sturgeon, reducing the invasion of pathogenic microorganisms, and promoting the recovery of the disease. During use, there will be no poor disease prevention and treatment effect due to insufficient dosage, and there will be no adverse effects on the Chinese sturgeon due to excessive dosage.
本发明再一方面提供一种饲料,包括如上所述的添加剂组合物。In another aspect, the present invention provides a feed comprising the additive composition as described above.
本发明提供的饲料由于包括上述添加剂组合物,因此,用于喂养感染皮肤病的中华鲟时,能够显著提高中华鲟的免疫力,提高染病中华鲟的治愈率。Since the feed provided by the present invention includes the additive composition, when used for feeding Chinese sturgeons infected with skin diseases, the immunity of Chinese sturgeons can be significantly improved, and the cure rate of infected Chinese sturgeons can be increased.
如上所述的饲料,还包括常规饲料,添加剂组合物与常规饲料的质量比为1.1:100。The feed as described above also includes conventional feed, and the mass ratio of the additive composition to the conventional feed is 1.1:100.
本发明不限定常规饲料的营养组分,可以选择本领域常用的中华鲟饲料。The present invention does not limit the nutritional components of conventional feeds, and the Chinese sturgeon feed commonly used in the art can be selected.
在一具体实施方式中,常规饲料包括粗蛋白≥44.0wt%,粗脂肪≥10.0wt%,粗纤维≤5.0wt%,粗灰分≤16.0wt%,总磷≥1.2wt%,赖氨酸≥2.5wt%。In a specific embodiment, the conventional feed comprises crude protein ≥44.0wt%, crude fat ≥10.0wt%, crude fiber ≤5.0wt%, crude ash ≤16.0wt%, total phosphorus ≥1.2wt%, and lysine ≥2.5wt%.
当常规饲料与添加剂组合物的质量比在上述范围内时,不仅能够有效控制喂养成本,而且具有优异的治疗中华鲟皮肤病的效果。When the mass ratio of the conventional feed to the additive composition is within the above range, it can not only effectively control the feeding cost but also has an excellent effect of treating the skin disease of the Chinese sturgeon.
本发明再一方面提供一种中华鲟的饲养方法,采用如上所述的饲料对中华鲟进行饲养。In another aspect, the present invention provides a method for raising Chinese sturgeon, which comprises raising Chinese sturgeon using the feed as described above.
由于采用上述饲料对中华鲟进行饲养,因此,本发明提供的饲养方法能够有效治疗中华鲟皮肤病。Since the Chinese sturgeon is raised with the above feed, the raising method provided by the present invention can effectively treat the skin disease of the Chinese sturgeon.
进一步地,在本发明的一具体实施方式中,饲养过程中日投喂量为体重的1.0%-1.3%,日投喂频次为2次/天,投喂时间间隔为12小时。Furthermore, in a specific embodiment of the present invention, the daily feeding amount during the feeding process is 1.0%-1.3% of the body weight, the daily feeding frequency is 2 times/day, and the feeding interval is 12 hours.
本发明中的日投喂量指每天投喂的饲料质量与中华鲟平均质量的比例。The daily feeding amount in the present invention refers to the ratio of the mass of feed fed every day to the average mass of Chinese sturgeon.
日投喂量为体重的1.0%-1.3%,举例来说,日投喂量包括但不限于1.0%、1.1%、1.2%、1.3%或其中任意两者组成的范围。The daily feeding amount is 1.0%-1.3% of body weight. For example, the daily feeding amount includes but is not limited to 1.0%, 1.1%, 1.2%, 1.3% or a range consisting of any two of them.
在一具体实施方式中,每天7:00进行投喂,投喂量为体重的0.5%-0.65%;19:00进行投喂,投喂量为体重的0.5%-0.65%。In a specific embodiment, the feeding is carried out at 7:00 every day, and the feeding amount is 0.5%-0.65% of the body weight; the feeding is carried out at 19:00 every day, and the feeding amount is 0.5%-0.65% of the body weight.
能够理解的是,可以根据养殖装置中中华鲟的摄食情况在上述范围内调整每次投喂量和投喂时间间隔。It is understandable that the feeding amount and feeding time interval can be adjusted within the above range according to the feeding situation of the Chinese sturgeon in the breeding device.
当按照上述投喂方式对中华鲟进行投喂时,不仅能够维持中华鲟摄入量平衡,使中华鲟更好的消化和吸收饲料及添加剂组合物,还能够使添加剂组合物充分发挥效果,提高中华鲟治愈率。When the Chinese sturgeon is fed according to the above feeding method, not only can the Chinese sturgeon's intake balance be maintained, so that the Chinese sturgeon can better digest and absorb the feed and additive composition, but also the additive composition can fully exert its effect and improve the cure rate of the Chinese sturgeon.
本发明再一方面提供一种如上所述的添加剂组合物作为制备治疗中华鲟皮肤病的药物中的应用。In another aspect, the present invention provides a use of the additive composition as described above in preparing a medicament for treating skin diseases of Chinese sturgeon.
详细而言,在制备治疗中华鲟皮肤病药物的过程中使用上述添加剂组合物。In detail, the additive composition is used in the process of preparing a drug for treating skin diseases of Chinese sturgeon.
本发明不限定制备治疗中华鲟皮肤病药物的具体制备工艺,可以选择本领域常见的制备方法。The present invention does not limit the specific preparation process of the drug for treating skin diseases of Chinese sturgeon, and a common preparation method in the art can be selected.
本发明再一方面提供一种药物组合物,包括如上所述的添加剂组合物。In another aspect, the present invention provides a pharmaceutical composition comprising the additive composition as described above.
由于本发明提供的药物组合物中包括上述添加剂组合物,因此在治疗中华鲟皮肤病的过程中具有显著效果。Since the pharmaceutical composition provided by the present invention includes the above-mentioned additive composition, it has a significant effect in the process of treating skin diseases of Chinese sturgeon.
进一步地,在本发明的一具体实施方式中,如上所述的药物组合物,还包括第一辅助药剂,所述第一辅助药剂按照质量份包括5-20份氟甲砜霉素、0.2份三磷酸腺苷二钠、0.5份辅酶A,100份复方氨基酸。Furthermore, in a specific embodiment of the present invention, the pharmaceutical composition as described above further comprises a first auxiliary agent, which comprises 5-20 parts of fluoroquinolone, 0.2 parts of adenosine triphosphate disodium, 0.5 parts of coenzyme A, and 100 parts of compound amino acids in parts by mass.
本发明中的第一辅助药剂为注射药剂。The first auxiliary drug in the present invention is an injectable drug.
详细而言,第一辅助药剂按照质量份包括5-20份氟甲砜霉素,举例来说,氟甲砜霉素质量份包括但不限于5份、10份、15份、20份或其中任意两者组成的范围。In detail, the first auxiliary agent includes 5-20 parts of fluoroquinolone by mass. For example, the mass of fluoroquinolone includes but is not limited to 5 parts, 10 parts, 15 parts, 20 parts or any two parts thereof.
能够理解的是,第一辅助药剂中还含有生理盐水。It is understandable that the first auxiliary agent also contains physiological saline.
在一具体实施方式中,第一辅助药剂按照质量份包括5-20份氟甲砜霉素、0.2份三磷酸腺苷二钠、0.5份辅酶A,100份复方氨基酸。In a specific embodiment, the first auxiliary agent includes 5-20 parts of fluoroquinolone, 0.2 parts of adenosine triphosphate disodium, 0.5 parts of coenzyme A, and 100 parts of compound amino acids in parts by mass.
本发明不限定第一辅助药剂的制备过程,在一具体实施方式中,首先用1mL生理盐水将三磷酸腺苷二钠溶解,用1mL生理盐水将辅酶A溶解,随后用注射器吸取溶解后的三磷酸腺苷二钠和辅酶A,然后依次吸取氟甲砜霉素和复方氨基酸,得到第一辅助药剂。The present invention does not limit the preparation process of the first auxiliary agent. In a specific embodiment, first, 1 mL of normal saline is used to dissolve adenosine triphosphate disodium, and 1 mL of normal saline is used to dissolve coenzyme A. Subsequently, a syringe is used to draw the dissolved adenosine triphosphate disodium and coenzyme A, and then fluoroquinolone and compound amino acids are drawn in sequence to obtain the first auxiliary agent.
为保障第一辅助药剂的效果,第一辅助药剂使用时需要现配现用。In order to ensure the effectiveness of the first auxiliary agent, the first auxiliary agent needs to be prepared and used immediately.
本发明中的氟甲砜霉素为动物专用的广谱抗生素,主要用于防治鱼类的气单胞菌病、假单胞菌病、弧菌病、屈挠杆菌病、链球菌病、巴斯德氏菌病、诺卡氏菌病、爱德华菌病、分枝杆菌病等细菌病。The fluoroquinolone in the present invention is a broad-spectrum antibiotic specially used for animals, and is mainly used to prevent and treat bacterial diseases such as Aeromonas disease, Pseudomonas disease, Vibrio disease, Flexibacterium disease, Streptococcus disease, Pasteurella disease, Nocardia disease, Edwardsiella disease, and mycobacterial disease in fish.
本发明中的三磷酸腺苷二钠作为一种辅酶类药物,参与体内脂肪、蛋白质、糖、核酸以及核苷酸的代谢,在生命活动中起着重要作用,与辅酶A联合使用可提供能量,恢复体质。The adenosine triphosphate disodium in the present invention is a coenzyme drug that participates in the metabolism of fat, protein, sugar, nucleic acid and nucleotide in the body and plays an important role in life activities. It can provide energy and restore physical fitness when used in combination with coenzyme A.
本发明中辅酶A为能量营养物质,体内乙酰化反应的辅酶,参与体内乙酰化反应,对糖、脂肪和蛋白质的代谢起重要的作用。In the present invention, coenzyme A is an energy nutrient, a coenzyme of acetylation reaction in the body, participates in acetylation reaction in the body, and plays an important role in the metabolism of sugar, fat and protein.
本发明中复方氨基酸(18AA)为一种营养补充剂,具有营养支持、增强免疫功能、修复组织损伤、促进组织愈合等功效和作用。The compound amino acid (18AA) in the present invention is a nutritional supplement having the effects and functions of nutritional support, enhancing immune function, repairing tissue damage, promoting tissue healing and the like.
在使用本发明的第一辅助药剂时,可以根据中华鲟的体重以及患病程度调整第一辅助药剂的使用量,例如在一具体实施方式中,第一辅助药剂与中华鲟的质量比为1:10000。When using the first auxiliary agent of the present invention, the dosage of the first auxiliary agent can be adjusted according to the weight and disease severity of the Chinese sturgeon. For example, in one specific embodiment, the mass ratio of the first auxiliary agent to the Chinese sturgeon is 1:10000.
在一具体实施方式中,本发明中的第一辅助药剂的使用方法如下:将感染皮肤病的中华鲟放置于治疗箱内,采用60-80ppm的MS-222麻醉病鱼,病鱼麻醉后,称量病鱼的体重,随后按照第一辅助药剂与染病中华鲟质量比为1:10000,通过胸鳍基部将第一辅助药剂注射到中华鲟体内,每天注射一次,连续5-8天为一个疗程,注射1-2个疗程。In a specific embodiment, the method for using the first auxiliary agent in the present invention is as follows: place the Chinese sturgeon infected with skin disease in a treatment box, use 60-80ppm MS-222 to anesthetize the diseased fish, weigh the diseased fish after anesthesia, and then inject the first auxiliary agent into the Chinese sturgeon through the base of the pectoral fin according to the mass ratio of the first auxiliary agent to the infected Chinese sturgeon of 1:10000, once a day, for 5-8 consecutive days as a course of treatment, and 1-2 courses of injection.
当药物组合物中包括添加剂组合物以及上述第一辅助药剂时,能够有效抑制细菌感染,促进皮肤组织修复和再生,提供细胞所需的能量和营养物质,进一步提高中华鲟皮肤病的治愈率。When the pharmaceutical composition includes the additive composition and the above-mentioned first auxiliary agent, it can effectively inhibit bacterial infection, promote skin tissue repair and regeneration, provide energy and nutrients required by cells, and further improve the cure rate of Chinese sturgeon skin diseases.
进一步地,在本发明的一具体实施方式中,药物组合物还包括第二辅助药剂,第二辅助药剂按照质量份包括1份紫草油、2份红霉素软膏、1份云南白药。Furthermore, in a specific embodiment of the present invention, the pharmaceutical composition also includes a second auxiliary agent, which includes 1 part of lithospermum oil, 2 parts of erythromycin ointment, and 1 part of Yunnan Baiyao in parts by mass.
本发明的第二辅助药剂用作外用药剂。The second auxiliary agent of the present invention is used as an external agent.
本发明中的紫草油具有抑菌抗炎、镇痛、清热凉血、止血等多种功效,对球菌、大肠杆菌、多种真菌有抑制作用,对体表皮肤创伤愈合具有显著疗效。The lithospermum oil of the present invention has multiple functions such as antibacterial and anti-inflammatory, analgesic, heat-clearing and blood-cooling, hemostasis, etc., has inhibitory effects on cocci, Escherichia coli, and various fungi, and has significant therapeutic effects on healing of skin wounds on the body surface.
本发明中的红霉素软膏是大环内酯类外用抗菌药物,可以杀灭多种革兰氏阳性菌和革兰氏阴性菌,主要用于脓包疮等化脓性皮肤病、小面积烧伤、溃疡面的感染和寻常痤疮。The erythromycin ointment of the present invention is a macrolide external antibacterial drug, which can kill a variety of gram-positive bacteria and gram-negative bacteria, and is mainly used for purulent skin diseases such as pustule, small-area burns, ulcer surface infections and acne vulgaris.
本发明中的云南白药具有活血化瘀、止血、消肿、消炎、促进伤口愈合等功效,可治疗跌打损伤、口腔溃疡、皮肤脓肿等。The Yunnan Baiyao in the present invention has the effects of promoting blood circulation and removing blood stasis, stopping bleeding, reducing swelling, reducing inflammation, promoting wound healing, etc., and can treat traumatic injuries, oral ulcers, skin abscesses, etc.
本发明中的第二辅助药剂只需要将1份紫草油、2份红霉素软膏、1份云南白药调和成膏状药剂即可。The second auxiliary agent in the present invention only needs to be prepared by mixing 1 part of lithospermum oil, 2 parts of erythromycin ointment and 1 part of Yunnan Baiyao into a paste-like agent.
本发明不限定第二辅助药剂的具体使用方法,在一具体实施方式中,将第二辅助药剂均匀涂抹在病灶表面,每天涂抹一次,连续5-8天为1个疗程,外用1-2个疗程。The present invention does not limit the specific use method of the second auxiliary agent. In a specific embodiment, the second auxiliary agent is evenly applied on the surface of the lesion, once a day, for 5-8 consecutive days as a course of treatment, and 1-2 courses of external use.
能够理解的是,可以根据中华鲟感染皮肤病的程度适当调整第二辅助药剂的使用过程以及用量。It is understandable that the use process and dosage of the second auxiliary agent can be appropriately adjusted according to the degree of skin disease infection in the Chinese sturgeon.
为使第二辅助药剂充分发挥作用,在使用第二辅助药剂前,还可以对中华鲟染病部位进行处理,在一具体实施方式中,采用碘伏或医用酒精棉球消毒处理中华鲟体表病灶处,然后用无菌注射器吸取血水。In order to make the second auxiliary agent fully play its role, the infected part of the Chinese sturgeon can be treated before using the second auxiliary agent. In a specific embodiment, the lesion on the surface of the Chinese sturgeon is disinfected with iodine or medical alcohol cotton balls, and then the blood is sucked out with a sterile syringe.
在添加剂组合物和第一辅助药剂以及第二辅助药剂的相互协同作用下,提供了更全面的治疗,包括减轻炎症、抑制感染、促进皮肤组织的修复和愈合,对于提高中华鲟皮肤病治愈率具有重要作用。The synergistic effect of the additive composition and the first auxiliary agent and the second auxiliary agent provides a more comprehensive treatment, including reducing inflammation, inhibiting infection, and promoting the repair and healing of skin tissue, which plays an important role in improving the cure rate of Chinese sturgeon skin diseases.
以下结合具体实施例对本发明提供的添加剂组合物进一步的说明。The additive composition provided by the present invention is further described below in conjunction with specific examples.
本发明中的中华鲟来自于中华鲟研究所宜昌实验站。The Chinese sturgeon in the present invention comes from the Yichang Experimental Station of the Chinese Sturgeon Research Institute.
实施例1Example 1
本实施例的添加剂组合物以及第一辅助药剂、第二辅助药剂的制备方法具体如下:The preparation methods of the additive composition, the first auxiliary agent, and the second auxiliary agent of this embodiment are as follows:
1)配制添加剂组合物:称取0.78mg维生素A(0.72份)、15.24mg泛酸钙(14份)、3.81mg叶酸(3.5份)、598.72mg维生素C(550份)、18.18mg维生素E(16.70份)、21.77mg维生素K3(20份)、10.34g板蓝根多糖(9500份),将上述组分混合均匀配制成添加剂组合物。1) Preparation of additive composition: weigh 0.78 mg vitamin A (0.72 parts), 15.24 mg calcium pantothenate (14 parts), 3.81 mg folic acid (3.5 parts), 598.72 mg vitamin C (550 parts), 18.18 mg vitamin E (16.70 parts), 21.77 mg vitamin K3 (20 parts), 10.34 g Radix Isatidis polysaccharide (9500 parts), and mix the above components evenly to prepare an additive composition.
2)配制第一辅助药剂:首先分别用1ml生理盐水将1.7mg三磷酸腺苷二钠(2份)和4.1mg辅酶A(5份)溶解,再用注射器吸取溶解后三磷酸腺苷二钠和辅酶A,然后依次吸取165.7mg氟甲砜霉素(200份)和828.5mg复方氨基酸(1000份)调和第一辅助药剂。2) Preparation of the first auxiliary agent: First, dissolve 1.7 mg of adenosine triphosphate disodium (2 parts) and 4.1 mg of coenzyme A (5 parts) in 1 ml of normal saline, then use a syringe to draw out the dissolved adenosine triphosphate disodium and coenzyme A, and then draw out 165.7 mg of fluoroquinolone (200 parts) and 828.5 mg of compound amino acids (1000 parts) in turn to mix the first auxiliary agent.
3)配制第二辅助药剂:称取1g紫草油、2g红霉素软膏、1g云南白药,三种药品混合均匀配制成第二辅助药剂。3) Preparation of the second auxiliary agent: weigh 1g of lithospermum oil, 2g of erythromycin ointment, and 1g of Yunnan Baiyao, and mix the three drugs evenly to prepare the second auxiliary agent.
上述添加剂组合组、第一辅助药剂、第二辅助药剂构成药物组合物。The above-mentioned additive combination group, the first auxiliary agent and the second auxiliary agent constitute a pharmaceutical composition.
实施例2Example 2
本实施例的添加剂组合物以及第一辅助药剂、第二辅助药剂的制备方法具体如下:The preparation methods of the additive composition, the first auxiliary agent, and the second auxiliary agent of this embodiment are as follows:
1)配制添加剂组合物:称取0.86mg维生素A(0.88份)、17.64mg泛酸钙(18份)、4.41mg叶酸(4.5份)、636.98mg维生素C(650份)、22.91mg维生素E(23.38份)、27.44mg维生素K3(28份)、10.29g板蓝根多糖(10500份),将上述组分混合均匀配制成添加剂组合物。1) Preparation of additive composition: weigh 0.86 mg vitamin A (0.88 parts), 17.64 mg calcium pantothenate (18 parts), 4.41 mg folic acid (4.5 parts), 636.98 mg vitamin C (650 parts), 22.91 mg vitamin E (23.38 parts), 27.44 mg vitamin K3 (28 parts), 10.29 g Radix Isatidis polysaccharide (10500 parts), and mix the above components uniformly to prepare an additive composition.
2)配制第一辅助药剂:首先分别用1ml生理盐水将1.9mg三磷酸腺苷二钠(2份)和4.7mg辅酶A(5份)溶解,再用注射器吸取溶解后三磷酸腺苷二钠和辅酶A,然后依次吸取47mg氟甲砜霉素(50份)和950mg复方氨基酸(1000份)调和成第一辅助药剂。2) Preparation of the first auxiliary agent: First, dissolve 1.9 mg of adenosine triphosphate disodium (2 parts) and 4.7 mg of coenzyme A (5 parts) in 1 ml of normal saline, then use a syringe to draw the dissolved adenosine triphosphate disodium and coenzyme A, and then draw 47 mg of fluoroquinolone (50 parts) and 950 mg of compound amino acids (1000 parts) in turn to mix into the first auxiliary agent.
3)配制第二辅助药剂:称取1g紫草油、2g红霉素软膏、1g云南白药,三种药品混合均匀配制成第二辅助药剂。3) Preparation of the second auxiliary agent: weigh 1g of lithospermum oil, 2g of erythromycin ointment, and 1g of Yunnan Baiyao, and mix the three drugs evenly to prepare the second auxiliary agent.
上述添加剂组合组、第一辅助药剂、第二辅助药剂构成药物组合物。The above-mentioned additive combination group, the first auxiliary agent and the second auxiliary agent constitute a pharmaceutical composition.
实施例3Example 3
本实施例的第一辅助药剂、第二辅助药剂的制备方法与实施例1相同,添加剂组合物的制备方法不同,具体如下:The preparation methods of the first auxiliary agent and the second auxiliary agent of this embodiment are the same as those of Embodiment 1, but the preparation method of the additive composition is different, which is specifically as follows:
步骤1)中,称取0.81mg维生素A(0.6份)、13.5mg泛酸钙(10份)、2.7mg叶酸(2份)、135.12mg维生素C(100份)、18.05mg维生素E(13.36份)、20.27mg维生素K3(15份)、10.81g板蓝根多糖(8000份),将上述组分混合均匀配制成添加剂组合物。In step 1), 0.81 mg vitamin A (0.6 parts), 13.5 mg calcium pantothenate (10 parts), 2.7 mg folic acid (2 parts), 135.12 mg vitamin C (100 parts), 18.05 mg vitamin E (13.36 parts), 20.27 mg vitamin K3 (15 parts), and 10.81 g isatis polysaccharide (8000 parts) were weighed and uniformly mixed to prepare an additive composition.
上述添加剂组合组、第一辅助药剂、第二辅助药剂构成药物组合物。The above-mentioned additive combination group, the first auxiliary agent and the second auxiliary agent constitute a pharmaceutical composition.
实施例4Example 4
本实施例的第一辅助药剂、第二辅助药剂的制备方法与实施例1相同,添加剂组合物的制备方法不同,具体如下:The preparation methods of the first auxiliary agent and the second auxiliary agent of this embodiment are the same as those of Embodiment 1, but the preparation method of the additive composition is different, which is specifically as follows:
步骤1)中,称取0.77mg维生素A(0.9份)、17.08mg泛酸钙(20份)、4.27mg叶酸(5份)、683.09mg维生素C(800份)、22.82mg维生素E(26.72份)、25.62mg维生素K3(30份)、10.25g板蓝根多糖(12000份),将上述组分混合均匀配制成添加剂组合物。In step 1), 0.77 mg vitamin A (0.9 parts), 17.08 mg calcium pantothenate (20 parts), 4.27 mg folic acid (5 parts), 683.09 mg vitamin C (800 parts), 22.82 mg vitamin E (26.72 parts), 25.62 mg vitamin K3 (30 parts), and 10.25 g Radix Isatidis polysaccharide (12000 parts) were weighed and uniformly mixed to prepare an additive composition.
上述添加剂组合组、第一辅助药剂、第二辅助药剂构成药物组合物。The above-mentioned additive combination group, the first auxiliary agent and the second auxiliary agent constitute a pharmaceutical composition.
实施例5Example 5
本实施例的第一辅助药剂、第二辅助药剂的制备方法与实施例1相同,添加剂组合物的制备方法不同,具体如下:The preparation methods of the first auxiliary agent and the second auxiliary agent of this embodiment are the same as those of Embodiment 1, but the preparation method of the additive composition is different, which is specifically as follows:
步骤1)中,称取0.82mg维生素A(0.8份)、16.50mg泛酸钙(16份)、4.13mg叶酸(4份)、618.86mg维生素C(600份)、20.67mg维生素E(20.04份)、24.75mg维生素K3(24份)、10.31g板蓝根多糖(10000),将上述组分混合均匀配制成添加剂组合物。In step 1), 0.82 mg vitamin A (0.8 parts), 16.50 mg calcium pantothenate (16 parts), 4.13 mg folic acid (4 parts), 618.86 mg vitamin C (600 parts), 20.67 mg vitamin E (20.04 parts), 24.75 mg vitamin K3 (24 parts), and 10.31 g Radix Isatidis polysaccharide (10000) were weighed and uniformly mixed to prepare an additive composition.
上述添加剂组合组、第一辅助药剂、第二辅助药剂构成药物组合物。The above-mentioned additive combination group, the first auxiliary agent and the second auxiliary agent constitute a pharmaceutical composition.
实施例6Example 6
本实施例的添加剂组合物、第一辅助药剂的制备方法与实施例1相同,不同之处在于,本实施例中药物组合物中不包括第二辅助药剂。The preparation methods of the additive composition and the first auxiliary agent in this embodiment are the same as those in Example 1, except that the second auxiliary agent is not included in the pharmaceutical composition in this embodiment.
实施例7Example 7
本实施例的添加剂组合物、第二辅助药剂的制备方法与实施例1相同,不同之处在于,本实施例中药物组合物中不包括第一辅助药剂。The preparation methods of the additive composition and the second auxiliary agent in this embodiment are the same as those in Example 1, except that the first auxiliary agent is not included in the pharmaceutical composition in this embodiment.
对比例1Comparative Example 1
本对比例的第一辅助药剂和第二辅助药剂的制备方法与实施例1相同,不同之处在于,本对比例中药物组合物中不包括添加剂组合物。The preparation method of the first auxiliary agent and the second auxiliary agent in this comparative example is the same as that in Example 1, except that the drug composition in this comparative example does not include an additive composition.
上述第一辅助药剂和第二辅助药剂构成药物组合物。The first auxiliary drug and the second auxiliary drug constitute a pharmaceutical composition.
对比例2Comparative Example 2
本对比例中的第一辅助药剂和第二辅助药剂的制备方法与实施例1相同,添加剂组合物的制备方法不同,具体如下:The preparation methods of the first auxiliary agent and the second auxiliary agent in this comparative example are the same as those in Example 1, but the preparation method of the additive composition is different, as follows:
步骤1)中,称取9.6mg维生素A(9份)、106.7mg泛酸钙(100份)、21.33mg叶酸(20份)、10.67g维生素C(10000份)、106.67mg维生素E(100份)、3.2mg维生素K3(3份)、85.33mg板蓝根多糖(80份),将上述组分混合均匀配制成添加剂组合物。In step 1), 9.6 mg vitamin A (9 parts), 106.7 mg calcium pantothenate (100 parts), 21.33 mg folic acid (20 parts), 10.67 g vitamin C (10,000 parts), 106.67 mg vitamin E (100 parts), 3.2 mg vitamin K 3 (3 parts), and 85.33 mg Radix Isatidis polysaccharide (80 parts) were weighed and uniformly mixed to prepare an additive composition.
测试例Test Case
将上述实施例1-5以及对比例2制备得到添加剂组合物与常规饲料按照质量比为1.1:100配制成饲料。The additive composition prepared in the above Examples 1-5 and Comparative Example 2 was mixed with conventional feed at a mass ratio of 1.1:100 to prepare feed.
中华鲟研究所宜昌实验站2020-2022年期间,1-2龄子二代中华鲟发生鱼病,采用下述方法对鱼病进行诊断治疗,当药物组合物中不含有添加剂组合物、第一辅助药剂以及第二辅助药剂的至少一种时,不进行使用该药剂或者组合物的处理。During 2020-2022, the Yichang Experimental Station of the Chinese Sturgeon Research Institute developed fish diseases in the second generation of Chinese sturgeons aged 1-2 years. The following method was used to diagnose and treat the fish diseases. When the drug composition did not contain at least one of the additive composition, the first auxiliary agent and the second auxiliary agent, the agent or composition was not used for treatment.
(1)皮肤病的诊断:发现病鱼后,检查病鱼,病鱼胸鳍、背鳍、臀鳍等基部或其它表皮部位出现红色小脓包,小脓包四周伴有红血丝症状。(1) Diagnosis of skin diseases: After discovering the diseased fish, check the diseased fish. Small red pustules will appear at the base of the pectoral fin, dorsal fin, anal fin or other epidermal parts of the diseased fish, and the pustules will be surrounded by red blood streaks.
(2)病鱼治疗:将病鱼捞起放入治疗箱内,病鱼的捞起等操作需要轻柔且带水操作,采用60-80ppm的MS-222麻醉病鱼,病鱼麻醉后,称量病鱼的体重;将第一辅助药剂与染病中华鲟质量比为1:10000的比例通过胸鳍基部注射到中华鲟体内,每天注射一次,连续5-8天为一个疗程,注射1-2个疗程;采用碘伏或医用酒精棉球消毒处理中华鲟体表病灶处,然后用无菌注射器吸取血水;将第二辅助药剂均匀地涂抹在病灶表面,每天涂抹一次,连续5-8天为一个疗程,外用1-2个疗程。(2) Treatment of sick fish: Pick up the sick fish and place them in a treatment box. The operation of picking up the sick fish needs to be done gently and with water. Use 60-80ppm MS-222 to anesthetize the sick fish. After the sick fish is anesthetized, weigh the sick fish. Inject the first auxiliary agent into the body of the Chinese sturgeon through the base of the pectoral fin at a mass ratio of 1:10000. Inject once a day for 5-8 consecutive days as a course of treatment, and inject 1-2 courses of treatment. Use iodine tincture or medical alcohol cotton balls to disinfect the lesions on the surface of the Chinese sturgeon, and then use a sterile syringe to absorb the blood. Apply the second auxiliary agent evenly on the surface of the lesions. Apply once a day for 5-8 consecutive days as a course of treatment, and use 1-2 courses of treatment.
(3)病鱼的饲喂。按照日投喂量为体重的1.0%-1.3%,日投喂频次为2次/天,投喂间隔为12小时的投喂规则对病鱼进行饲喂。(3) Feeding of sick fish: Feed sick fish according to the feeding rule of 1.0%-1.3% of body weight per day, 2 times per day, and 12 hours interval between feedings.
统计各个实施例以及对比例提供的药物组合物的治疗效果,具体见表1。The therapeutic effects of the pharmaceutical compositions provided in various embodiments and comparative examples are statistically analyzed, as shown in Table 1.
表1Table 1
最后应说明的是:以上各实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述各实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的范围。Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. However, these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410586060.XA CN118303531B (en) | 2024-05-11 | 2024-05-11 | A kind of additive composition and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410586060.XA CN118303531B (en) | 2024-05-11 | 2024-05-11 | A kind of additive composition and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN118303531A true CN118303531A (en) | 2024-07-09 |
| CN118303531B CN118303531B (en) | 2025-02-11 |
Family
ID=91725940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410586060.XA Active CN118303531B (en) | 2024-05-11 | 2024-05-11 | A kind of additive composition and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118303531B (en) |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010068226A (en) * | 2000-01-03 | 2001-07-23 | 민경우 | composition containing chitosan oligo saccharide and aminoethyl sulfonic acid for use as fodder and drinking water additives |
| JP2005269913A (en) * | 2004-03-23 | 2005-10-06 | Daicho Kikaku:Kk | Fish feed additive, and fish feed |
| CN1969863A (en) * | 2006-11-30 | 2007-05-30 | 天津生机集团有限公司 | Vitamin composition used for marine product |
| CN101496812A (en) * | 2008-01-28 | 2009-08-05 | 中国水产科学研究院东海水产研究所 | Compositional agent for rapid healing large-sized Acipenser sinensis with serious injury |
| RU2012136225A (en) * | 2012-08-23 | 2014-02-27 | Наталья Викторовна Гоман | FODDER ADDITIVE FOR ANIMALS AND BIRDS |
| CN104719677A (en) * | 2015-04-13 | 2015-06-24 | 云南农业大学 | Sturgeon compound feed with effect of increasing rubber seed cake utilization rate by aid of egg yolk powder |
| CN105614171A (en) * | 2015-12-30 | 2016-06-01 | 防城港市那旺生态农业科技有限公司 | Sturgeon antibacterial feed additive |
| CN106069901A (en) * | 2016-06-17 | 2016-11-09 | 中国长江三峡集团公司中华鲟研究所 | A kind of quickly discriminating mandarin sturgeon property method for distinguishing and used tool |
| CN107183415A (en) * | 2017-07-12 | 2017-09-22 | 华中农业大学 | The artifical compound feed and preparation method and application of a kind of mandarin sturgeon parent population gonad development |
| CN107646755A (en) * | 2017-09-22 | 2018-02-02 | 贵州省松桃吉光农业发展有限责任公司 | A kind of sturgeon cultivation method |
| CN107667928A (en) * | 2017-09-30 | 2018-02-09 | 安徽麒麟正大饲料有限公司 | It is a kind of to be used to prevent and treat premix of mixed breeding fish disease viral disease and preparation method thereof |
| CN114431363A (en) * | 2021-12-30 | 2022-05-06 | 益阳市泊湖岭绿色农林有限公司 | Green efficient feed for paddlefish |
| US20220142205A1 (en) * | 2020-11-11 | 2022-05-12 | Guangdong Ocean University | Feed for enhancing immunity of tilapia and preparation method thereof |
| CN117297003A (en) * | 2023-10-20 | 2023-12-29 | 中国长江三峡集团有限公司中华鲟研究所 | Compound feed for promoting gonad development of Acipenser sinensis and preparation method thereof |
-
2024
- 2024-05-11 CN CN202410586060.XA patent/CN118303531B/en active Active
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010068226A (en) * | 2000-01-03 | 2001-07-23 | 민경우 | composition containing chitosan oligo saccharide and aminoethyl sulfonic acid for use as fodder and drinking water additives |
| JP2005269913A (en) * | 2004-03-23 | 2005-10-06 | Daicho Kikaku:Kk | Fish feed additive, and fish feed |
| CN1969863A (en) * | 2006-11-30 | 2007-05-30 | 天津生机集团有限公司 | Vitamin composition used for marine product |
| CN101496812A (en) * | 2008-01-28 | 2009-08-05 | 中国水产科学研究院东海水产研究所 | Compositional agent for rapid healing large-sized Acipenser sinensis with serious injury |
| RU2012136225A (en) * | 2012-08-23 | 2014-02-27 | Наталья Викторовна Гоман | FODDER ADDITIVE FOR ANIMALS AND BIRDS |
| CN104719677A (en) * | 2015-04-13 | 2015-06-24 | 云南农业大学 | Sturgeon compound feed with effect of increasing rubber seed cake utilization rate by aid of egg yolk powder |
| CN105614171A (en) * | 2015-12-30 | 2016-06-01 | 防城港市那旺生态农业科技有限公司 | Sturgeon antibacterial feed additive |
| CN106069901A (en) * | 2016-06-17 | 2016-11-09 | 中国长江三峡集团公司中华鲟研究所 | A kind of quickly discriminating mandarin sturgeon property method for distinguishing and used tool |
| CN107183415A (en) * | 2017-07-12 | 2017-09-22 | 华中农业大学 | The artifical compound feed and preparation method and application of a kind of mandarin sturgeon parent population gonad development |
| CN107646755A (en) * | 2017-09-22 | 2018-02-02 | 贵州省松桃吉光农业发展有限责任公司 | A kind of sturgeon cultivation method |
| CN107667928A (en) * | 2017-09-30 | 2018-02-09 | 安徽麒麟正大饲料有限公司 | It is a kind of to be used to prevent and treat premix of mixed breeding fish disease viral disease and preparation method thereof |
| US20220142205A1 (en) * | 2020-11-11 | 2022-05-12 | Guangdong Ocean University | Feed for enhancing immunity of tilapia and preparation method thereof |
| CN114431363A (en) * | 2021-12-30 | 2022-05-06 | 益阳市泊湖岭绿色农林有限公司 | Green efficient feed for paddlefish |
| CN117297003A (en) * | 2023-10-20 | 2023-12-29 | 中国长江三峡集团有限公司中华鲟研究所 | Compound feed for promoting gonad development of Acipenser sinensis and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118303531B (en) | 2025-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013507328A (en) | Compositions containing benzoic acid as an active component in combination with an organic acid preservative, and uses thereof | |
| WO2025113405A1 (en) | Use of l-theanine in preparation of formulation for treating vaginitis | |
| CN117281839A (en) | Application of bacteroides sally CSP6 in preparing medicine and/or food for treating and/or preventing inflammatory bowel disease | |
| CN102363040B (en) | Antimicrobial peptide preparation for mucosal tissues | |
| CN118303531A (en) | Additive composition and application thereof | |
| CN119950416A (en) | A kind of andrographolide gel and its preparation method and application | |
| CN116492397B (en) | Preparation for improving cow breeding performance, preparation method thereof and method for improving cow breeding performance | |
| CN119530099A (en) | Bifidobacterium adolescentis beneficial to skin and its derivatives and applications | |
| CN117298166A (en) | Application of Wallace melon compound fermented beverage in the preparation of drugs for alleviating ulcerative colitis and/or intestinal flora disorders | |
| WO2025010846A1 (en) | Use of lysophosphatidic acid in prevention and treatment of porcine infectious diarrhea | |
| CN111905058A (en) | Pharmaceutical composition for skin mucosa nursing and wound repair and preparation method thereof | |
| CN115444074A (en) | A kind of quercetin compound traditional Chinese medicine feed additive and its preparation method and application | |
| CN106667984A (en) | Small-molecule substance capable of enhancing antibacterial drug effects of florfenicol | |
| CN108635362B (en) | Pharmaceutical composition for treating diabetic foot | |
| CN114522268B (en) | A kind of skin repair material and its preparation method and application | |
| CN111557969A (en) | Medicine for treating hoof diseases and preparation method and application thereof | |
| TWI869314B (en) | Use of lactobacillus fermentum gkf3 in manufacturing wound external composition for facilitating skin wound healing and anti-oxidation | |
| CN1272007C (en) | Compound formulation for preventing and treating broiler ascites syndrome | |
| CN117959328A (en) | A plant extract composition for preventing and treating coccidia, and its preparation method and application | |
| CN121058816A (en) | A gut health functional additive for long-snout catfish based on Soxhletella metabolites | |
| CN118649155A (en) | Application of erythritol in the preparation of drugs for alleviating animal mammary fibrosis | |
| CN1650950A (en) | A kind of traditional Chinese medicine for treating bovine endometritis | |
| CN101049363A (en) | Composition of medication of skin prurigo agent, preparation method | |
| CN114452375A (en) | Application of a Kangfuxin solution and FGF-10 in synergistic regulation of intestinal flora and improvement of immune system homeostasis | |
| CN121153798A (en) | A feed additive for preventing and treating shrimp sporozoan disease and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |